Monoclonal Antibodies in Relapsed Multiple Myeloma with Cristina Gasparetto, MD: Case 2

Case Scenario 2:

January 2015

• The patient is a 72-year old female who was diagnosed with ISS stage I multiple myeloma.
• She is an insulin dependent diabetic who is experiencing peripheral neuropathy.
• Her cytogenetics were classified as standard risk.
• Performance status 1.
• She received treatment with lenalidomide (25 mg daily) and low-dose dexamethasone with a good response.
• After a year she decided to come off of lenalidomide therapy.

     July 2016

• Six months after stopping therapy, the patient had increasing fatigue and weakness.
• CT scan revealed several bone lesions.
• Patient was started on daratumumab, lenalidomide and dexamethasone